USFDA: Glenmark, Granules, Zydus Recall Products in US

By By Rediff Money Desk, New Delhi
Sep 28, 2025 10:27
Glenmark, Granules India, Sun Pharma, Zydus, Unichem recall products in the US due to manufacturing issues, says USFDA report.
New Delhi, Sep 28 (PTI) Domestic drugmakers Glenmark, Granules India, Sun Pharma, Zydus and Unichem are recalling products in the US market for various manufacturing issues, according to the US Food and Drug Administration (USFDA).

The drugmakers are voluntarily recalling affected lots in the American market, the US health regulator said in its latest Enforcement Report.

A US-based subsidiary of the Mumbai-based Glenmark Pharmaceuticals is recalling 13,824 Azelaic Acid Gel tubes produced at the company's Goa plant due to "CGMP deviations" following market complaints received for gritty texture, USFDA said.

New Jersey-based Glenmark Pharmaceuticals Inc, USA, initiated the Class II nationwide recall on September 17.

As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Hyderabad-based Granules India is recalling over 49,000 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, extended-release capsules in multiple strengths due to "failed impurities/degradation specifications", USFDA said.

The US-based arm of the company issued the Class III recall on August 28.

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

The US health regulator stated that a US-based subsidiary of the drug major Sun Pharma is recalling 1,870 kits of renal imaging agent.

The Class II recall announced on September 3 is due to the failed dissolution specifications, it added.

Zydus Pharmaceuticals (USA) Inc, a unit of Ahmedabad-based drugmaker, is recalling 8,784 bottles of antiviral drug Entecavir tablets, due to "failed impurity/ degradation specifications," USFDA stated.

The company initiated the Class II recall on September 4.

Another drug firm Unichem Pharmaceuticals USA Inc is recalling 230 90-count bottles for label mix-up, USFDA said.

The East Brunswick-based firm issued the Class I recall on August 27, it added.

India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.
Source: PTI
Read More On:
usfdaglenmark recallgranules india recallzydus recalldrug recall us
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Corona Remedies IPO Subscribed 137 Times

Corona Remedies IPO subscribed 137.04 times on final day. QIBs subscribed 278.52 times,...

India Logistics Cost Down to 9%: Gadkari

Nitin Gadkari says India has met its target to reduce logistics cost to 9% of GDP due...

Coal Mining: Panel Urges Faster Green Clearances

Parliamentary panel urges faster environmental & forest clearances for coal mining...

DCM Shriram & Bayer Crop Science Collaboration

DCM Shriram and Bayer Crop Science partner to explore agricultural opportunities in...

Silver Price Soars to Rs 1.92 Lakh/kg on Global...

Silver prices surge Rs 11,500 to Rs 1.92 lakh/kg in Delhi amid strong global cues. Gold...

Urea Fixed Costs to Rise for Manufacturers

Govt plans to raise fixed costs for urea makers by year-end. Decision expected soon,...

Bullion Rates Today: Gold & Silver Prices

Check today''s closing bullion rates in Bengaluru. Gold (22K & 24K) prices per gram and...

Bank of India Raises Rs 2,500 Cr via Tier II Bonds

Bank of India (BoI) raised Rs 2,500 crore through Basel III-compliant Tier II bonds at...

Cipla Launches Obesity & Diabetes Drug Yurpeak

Cipla launches Yurpeak (tirzepatide), a weekly injectable for obesity and type-2...

Sebi Eases KYC for NRIs, Removes Physical Presence

Sebi relaxes re-KYC for NRIs, removing physical presence requirement for digital...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com